Effect of recombinant feline interferon-ω alone and in combination with chemotherapeutic agents on putative tumour-initiating cells and daughter cells derived from canine and feline mammary tumours

C. Penzo, M. Ross, R. Muirhead, R. Else, D.J. Argyle

Research output: Contribution to journalArticlepeer-review

Abstract

Interferons (IFNs) are naturally produced cytokines with multiple important biological functions. The activity of recombinant feline IFN- (rFeIFN-) alone and in combination with chemotherapeutic drugs was tested on canine and feline mammary carcinoma cell lines (REM134 and CAT-MT) and putative tumour-initiating cells (TIC) derived from these cell lines by sphere assay. Viability was measured by chemoluminescence and a one-way analysis of variance and Student's t-tests were used for statistical analysis. rFeIFN- showed in vitro antitumour activity on feline and canine mammary carcinoma cells and putative TICs with a dose-dependent and target cell-specific action. Putative TICs were more resistant to the action of rFeIFN- compared with daughter REM134 and CAT-MT cells. REM134 cells and TICs were more sensitive to rFeIFN- compared with the feline counterparts. An additive effect was noticed between rFeIFN- and conventional anticancer drugs, in particular following co-culture of cells with anthracycline drugs. The results suggest that rFeIFN- warrants further investigation as a therapeutic adjunct in feline and canine mammary tumours.

Original languageEnglish
Pages (from-to)222-229
Number of pages8
JournalVeterinary and Comparative Oncology
Volume7
Issue number4
DOIs
Publication statusPublished - 1 Dec 2009

Keywords

  • chemotherapy
  • interferon
  • mammary tumours
  • small animal
  • stem cells
  • tumour biology

Fingerprint

Dive into the research topics of 'Effect of recombinant feline interferon-ω alone and in combination with chemotherapeutic agents on putative tumour-initiating cells and daughter cells derived from canine and feline mammary tumours'. Together they form a unique fingerprint.

Cite this